

Advancing Pharmaceutical Sciences, Careers, and Community

Press Release

4/11/2023

For more information: Rebecca Stauffer AAPS Communications Manager staufferr@aaps.org

Joel Dudley, Ph.D, Biotechnology Expert and Venture Capitalist, to Discuss Current Economic Environment at AAPS National Biotechnology Conference

Arlington, VA—Joel Dudley, Ph.D., a Partner at Innovation Endeavors, a venture capital firm focused on technology, will present the opening plenary at the AAPS National Biotechnology Conference, Sunday, April 23 at 3 p.m.

Dudley is an expert in the biotechnology space with experience in evaluating biotechnology firms and start-ups. While at the Icahn School of Medicine, Dr. Dudley was one of the authors of a 2016 paper published in the *Journal of Clinical Investigation* that compared results from a blood sample tested using Theranos' technology with traditional blood testing services. The authors found that the Theranos product "flagged tests outside their normal range 1.6× more often than other testing services."

Prior to Innovation Endeavors, Dr. Dudley served as Chief Scientific Officer for Tempus, a health tech start-up. He was also an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai.

"AAPS is honored to have Joel Dudley present the opening plenary for the National Biotechnology Conference," AAPS Executive Director Tina Morris, Ph.D., said. "His insights will be valuable at a time when the biotechnology sector must shrewdly navigate a more challenging economic environment in order to continue delivering life-saving innovations to patients."

"As an organization, AAPS strives to present quality science. Joel Dudley exemplifies a commitment to scientific ethics and leadership within our industry that we wanted to highlight at this year's National Biotechnology Conference," AAPS President Patrick Sinko, Ph.D., said.

Dr. Dudley's talk will examine the current economic environment for biotechnology firms and leveraging A.I. for pharmaceutical and technology development.

###

American Association of Pharmaceutical Scientists (AAPS) is a 501(c)(3) non-profit association of more than 7,000 scientists and professionals employed in academia, industry, regulatory, and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online. www.aaps.org